Roth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7
Roth Capital analyst Boobalan Pachaiyappan maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $8 to $7.
Stocks · News reference
Annovis Bio Announces Full Enrollment Of Its Phase 3 Trial Of Buntanetap In Patients With Early Alzheimer’s Disease; The Trial Enrolled 850 Patients; Symptomatic Data Readout Expected In Q1 2027, and Disease-Modifying Data Readout Anticipated in Q1 2028
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Annovis Bio, Inc. (ANVS)
Filed: 2026-08-14 AccNo: 0001104659-26-097091 Size: 267 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Annovis Bio Q2 EPS $(0.40) Beats $(0.45) Estimate
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.45) by 11.11 percent. This is a 25 percent decrease over losses of $(0.32) per share from the same